Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose is to determine whether induction and consolidation treatment with Carfilzomib,
Lenalidomide and Dexamethasone (CRd), within an intensive program, warrant further
investigation in clinical trials.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Toulouse
Collaborators:
Celgene Celgene Corporation Onyx Therapeutics, Inc.